DFPI Appeals Loss in OppFi True Lender Case
A California judge rejected the state's rent-a-bank theory against OppFi. Now the regulator wants three appellate judges to reverse him.
A California judge rejected the state's rent-a-bank theory against OppFi. Now the regulator wants three appellate judges to reverse him.
Novo paid $725 million for ziltivekimab in 2020. The IL-6 drug just missed its primary cardiovascular endpoint, and shares dropped 9% within hours.
Four months after a $30M capital infusion, Lineage Bank faces new FDIC scrutiny, its second consent order since the Synapse collapse.
Moderna's norovirus shot missed its Phase 3 bar, but the real verdict lands August 5 with FDA's call on its first mRNA flu vaccine.
DOJ's cartel line about Scoular's $10.2M FCPA deal appears once in a 52-page document, copy-pasted straight from the press release.
A New York judge refused to toss the AG's fraud suit against EWS, letting claims over $1 billion in Zelle scam losses head to discovery.
No equity changed hands, but Lilly's $750M Ohio investment says more about its manufacturing supply strategy than any acquisition of Resilience would.
Capricor's CEO won't rule out suing FDA after a 9-3 adcomm loss she blames on an unsigned statistical draft the agency used as its benchmark.
New York wants triple damages from Kalshi for unlicensed gambling. The CFTC already sued to stop the state from touching prediction markets at all.
Amazon finished wiring its $50 billion into OpenAI five months early, but its SEC filing never explains why the AGI-or-IPO trigger got skipped.
Anthropic's own AI broke into three organizations' live systems during a security test, and two victims never noticed until the call came.
Okta paid ~2.5x Permiso's last funding round, per a source familiar with the deal. CyberArk's Venafi buy set the machine-identity comp a year earlier.
CareCloud sat on the details for four months. The new filing shows SSNs, bank accounts and passports exposed together in a six-day AWS breach.
xAI says Minnesota's $500,000-per-image penalty leaves it no choice but to gut Grok Imagine's editing tools for users before August 1.
Two shells, $478M in fresh cash: Caldera values a failed biotech's carcass at $18M, Vidya's buyer keeps just 0.9% of the combined company.